Khadijeh Dizaji Asl | Oncology | Editorial Board Member

Published on by Health Scientists

Editorial Board Member

Khadijeh Dizaji Asl
Islamic Azad University, Iran

                        Khadijeh Dizaji Asl
Affiliation Islamic Azad University
Country Iran
Scopus ID 57221391321
Documents 21
Citations 207
h-index 8
Subject Area Oncology
Event Health Scientists Awards
ORCID 0000-0003-0920-9583

Khadijeh Dizaji Asl is an oncology-focused researcher affiliated with Islamic Azad University, Iran. Her scholarly activities contribute to the advancement of cancer-related research, clinical understanding, and evidence-based scientific inquiry. Through publications indexed in major academic databases and an established citation record, she has demonstrated sustained engagement with oncology research and interdisciplinary scientific collaboration.[1][2]

Abstract

Khadijeh Dizaji Asl is an oncology researcher affiliated with Islamic Azad University whose scholarly record reflects active participation in cancer-related investigations and biomedical research. Her publications address topics associated with oncology, disease mechanisms, clinical outcomes, and evidence-based healthcare approaches. Indexed academic outputs, citation performance, and an established h-index indicate measurable scientific visibility within her research field. Through collaboration, publication, and dissemination of findings, she contributes to the broader understanding of oncological challenges and supports the development of knowledge that informs future research directions and clinical applications in cancer science.[1][2]

Keywords

Oncology, Cancer Research, Clinical Oncology, Biomedical Science, Tumor Biology, Medical Research, Health Sciences, Evidence-Based Medicine, Cancer Studies, Scientific Publications

Introduction

Khadijeh Dizaji Asl has developed a research profile centered on oncology and related biomedical disciplines. Her scholarly work contributes to the growing body of scientific literature addressing cancer mechanisms, treatment perspectives, and healthcare outcomes. Academic indexing and citation metrics demonstrate continued engagement with internationally visible research activities.[1]

Research Profile

Affiliated with Islamic Azad University, Khadijeh Dizaji Asl has authored publications indexed in Scopus and other academic platforms. Her research interests primarily involve oncology-related investigations, scientific collaboration, and dissemination of evidence supporting advancements in cancer research and healthcare knowledge.[1][2]

Research Contributions

Her scholarly contributions include participation in studies that enhance understanding of oncological processes and clinical implications. Through peer-reviewed publications, she has supported scientific discussion surrounding cancer research, contributing data and analyses that strengthen evidence-based approaches within the field.[1][3]

Publications

The publication portfolio of Khadijeh Dizaji Asl includes twenty-one indexed documents with measurable citation performance. Her research outputs appear within recognized scholarly channels and contribute to the dissemination of oncology-focused findings relevant to researchers, clinicians, and healthcare stakeholders.[1]

Research Impact

With more than two hundred citations and an h-index of eight, her work demonstrates scholarly recognition within the scientific community. These indicators suggest that published findings have informed subsequent studies and contributed to ongoing academic discourse in oncology research.[1][2]

Award Suitability

Based on her documented research productivity, citation record, and commitment to oncology scholarship, Khadijeh Dizaji Asl demonstrates qualifications aligned with recognition programs that value scientific contribution, academic engagement, and advancement of health-related research within the international research community.[4]

Conclusion

Khadijeh Dizaji Asl has established a visible academic presence through oncology-focused research, indexed publications, and scholarly citations. Her contributions support scientific understanding of cancer-related topics and reflect ongoing participation in research activities that advance evidence-based knowledge and healthcare scholarship.[1]

References

  1. Elsevier. (n.d.). Scopus author details: Khadijeh Dizaji Asl, Author ID 57221391321. Scopus.https://www.scopus.com/authid/detail.uri?authorId=57221391321
  2. ORCID. (n.d.). Khadijeh Dizaji Asl: ORCID record 0000-0003-0920-9583.https://orcid.org/0000-0003-0920-9583
  3. Google Scholar. (n.d.). Scholar profile of Khadijeh Dizaji Asl.https://scholar.google.com/citations?user=fyQaW6YAAAAJ&hl=en&oi=ao
  4. ResearchGate. (n.d.). Khadijeh Dizaji Asl researcher profile.https://www.researchgate.net/profile/Khadijeh-Dizaji-Asl

Dimitrios Bouklas | Oncology | Innovative Research Award

Published on by Health Scientists

Innovative Research Award

Dimitrios Bouklas
General Hospital of Athens “G. Gennimatas”
          Dimitrios Bouklas
Affiliation General Hospital of Athens “G. Gennimatas”
Country Greece
Scopus ID 57372362800
Documents 5
Citations 2
h-index 1
Subject Area Oncology
Event Health Scientists Awards
ORCID 0000-0002-5858-0357

Dimitrios Bouklas is affiliated with the General Hospital of Athens “G. Gennimatas” in Greece and contributes to oncology-related clinical and scientific investigations. His scholarly profile demonstrates engagement in cancer research and healthcare studies, supported by indexed publications and citation records available through international academic databases.[1][2]

Abstract

Dimitrios Bouklas has developed a research profile focused on oncology and clinical healthcare studies within a hospital-based environment. His published work contributes to understanding cancer-related conditions, patient management approaches, and evidence-based medical practice. Indexed publications demonstrate participation in multidisciplinary scientific investigations and collaboration with healthcare professionals. Through dissemination of peer-reviewed research, his work supports ongoing efforts to improve clinical knowledge and patient outcomes. The available scholarly metrics, including indexed documents, citations, and author identifiers, indicate active engagement in scientific communication and contribution to contemporary oncology literature and healthcare research initiatives.[1][2]

Keywords

Oncology, Cancer Research, Clinical Oncology, Healthcare Research, Medical Science, Hospital-Based Research, Cancer Care, Clinical Studies, Patient Outcomes, Scientific Publications

Introduction

The advancement of oncology relies on continuous clinical investigation and evidence-based practice. Dimitrios Bouklas contributes to this field through participation in research activities associated with cancer care, clinical assessment, and healthcare improvement, supporting scientific understanding and the translation of research findings into medical practice.[1]

Research Profile

His academic profile is represented through indexed publications in oncology and related healthcare disciplines. Affiliated with a major healthcare institution in Greece, he participates in scientific studies addressing clinical challenges, patient care considerations, and disease-related investigations within contemporary medical research environments.[1][2]

Research Contributions

Dimitrios Bouklas has contributed to peer-reviewed investigations involving oncology-focused clinical research. His work supports scientific discussion on disease management, healthcare outcomes, and multidisciplinary medical collaboration. These contributions enhance the evidence base available to clinicians and researchers working in cancer-related healthcare settings.[1]

Publications

The researcher’s publication record includes indexed scientific articles documented within Scopus and other scholarly platforms. These works reflect involvement in oncology and clinical medicine research, contributing to the dissemination of healthcare knowledge through peer-reviewed academic literature and professional scientific communication.[1][3]

Research Impact

Research impact is reflected through citation activity, indexed publications, and professional visibility across scholarly databases. Although at an early citation stage, the documented work contributes to oncology literature and supports ongoing academic engagement within clinical and healthcare research communities.[1][4]

Award Suitability

Dimitrios Bouklas demonstrates qualifications aligned with the objectives of the Innovative Research Award through documented scholarly activity, oncology-focused investigations, and participation in scientific publication. His commitment to advancing clinical knowledge and supporting evidence-based healthcare makes him a relevant candidate for academic recognition.[1][2]

Conclusion

The academic profile of Dimitrios Bouklas reflects meaningful engagement in oncology research and scientific communication. Through publications, institutional affiliation, and participation in healthcare studies, he contributes to the advancement of medical knowledge and demonstrates characteristics consistent with emerging research excellence.[1]

References

  1. Elsevier. (n.d.). Scopus Author Details: Dimitrios Bouklas, Author ID 57372362800. Scopus.

    https://www.scopus.com/authid/detail.uri?authorId=57372362800

  2. ORCID. (n.d.). Dimitrios Bouklas – ORCID Record.

    https://orcid.org/0000-0002-5858-0357

  3. ResearchGate. (n.d.). Dimitrios Bouklas Research Profile and Publications.

    https://www.researchgate.net/profile/Dimitrios-Bouklas

  4. Google Scholar. (n.d.). Dimitrios Bouklas Citation Profile.

    https://scholar.google.com/citations?user=h6mhYUIAAAAJ&hl=en&oi=ao

Lingyu Ding | Oncology | Distinguished Scientist Award

Published on by Health Scientists

Mrs. Lingyu Ding | Oncology | Distinguished Scientist Award

clinical nurse | Jiangsu province hospital | China

Lingyu Ding is a distinguished registered nurse at the Colorectal Surgery Department of The First Affiliated Hospital with Nanjing Medical University, specializing in oncology nursing, perioperative rehabilitation, and cancer-related frailty. She has made significant contributions to the development and validation of frailty assessment models for cancer survivors and has designed and pilot-tested multimodal interventions to manage frailty, demonstrating a strong commitment to improving patient outcomes. Her research has been published extensively in peer-reviewed journals, encompassing systematic reviews, meta-analyses, and observational studies that explore preoperative frailty, sedentary behavior, handgrip strength asymmetry, and postoperative outcomes among older adults with cancer. Lingyu has successfully secured and led a project funded by the National Natural Science Foundation of China, reflecting her leadership and research capabilities, and she actively engages in collaborative projects with multidisciplinary teams. Her work has been recognized with prestigious awards for excellence in professional practice, innovative nursing interventions, and outstanding young talent, underscoring both her academic and clinical impact. Beyond her research, Lingyu contributes to the scholarly community as a peer reviewer for international journals, ensuring the rigor and quality of scientific publications. Her expertise spans both quantitative and qualitative research methodologies, including randomized controlled trials, questionnaire design, phenomenological research, and grounded theory, complemented by proficiency in statistical analysis and academic writing. Through her clinical practice, research, and scholarly activities, Lingyu Ding advances the understanding and management of frailty in cancer patients, bridging the gap between evidence-based research and practical healthcare applications, and making a meaningful impact on patient care, health outcomes, and the broader field of oncology nursing. She has 361 citations from 33 documents with an h-index of 11.

Profile: Scopus 

Featured Publications

1. Willingness, preference, and resistance to frailty intervention for older gastric cancer based on stakeholder perspective: A qualitative study. (2025). BMC Geriatrics. Open access.

2. Clinical characteristics and correlation between preoperative frailty and metabolic syndrome among older patients with gastric cancer. (2025). Chinese General Practice.

3.BMI trajectories, associations with outcomes and predictors in elderly gastric cancer patients undergoing radical gastrectomy: A prospective longitudinal observation study. (2025). Journal of Cancer Survivorship.

Rasha Elsabagh | Oncology | Research Excellence Award

Published on by Health Scientists

Dr. Rasha Elsabagh | Oncology | Research Excellence Award

Researcher | Animal Health Research Institute(AHRI) | Egypt

Rasha H. Elsabagh is a multidisciplinary immunology specialist and cancer stem cell researcher with extensive expertise spanning stem cell biology, immuno-oncology, translational cancer research, and veterinary biomedical sciences. She currently serves as a researcher at the Animal Health Research Institute, where her work integrates advanced immunological diagnostics, molecular biology, and national livestock immunization programs that directly contribute to animal health surveillance and disease control. Her academic training culminated in a doctoral degree in cancer immunology from Cairo University, where her research focused on circulating cancer stem cells and photothermal nanotherapy as predictive and monitoring tools for tumor response. She has conducted advanced international research training at University of California San Francisco, gaining high-level proficiency in flow cytometry, immunofluorescence, and human stem cell analysis, and later expanded her translational oncology experience as a visiting research fellow at the Cancer Institute of Montpellier, working on nanoparticle-mediated RNA delivery to tumor-infiltrating immune cells. Her scientific output includes multiple peer-reviewed publications in high-impact journals and international conference proceedings, with her work receiving sustained scholarly citations and global academic recognition. Her research collaborations span institutions in North America, Europe, and the Middle East, reflecting her active role in international scientific networks in stem cell biology, cancer immunology, and nanomedicine. Beyond laboratory research, she contributes to national capacity building through scientific training, quality assurance in diagnostic immunology, and public health–oriented animal disease control programs. Her work has direct societal impact through improvements in cancer diagnostics, advancement of immunotherapeutic strategies, and strengthening of zoonotic disease surveillance, positioning her as a globally engaged scientist at the intersection of experimental research, translational medicine, and public health. She has 2 citations from 2 documents with an h-index of 1.

Profiles: Google Scholar | Scopus | ORCID

Featured Publications

1. Xiao, T., Eze, U. C., Charruyer-Reinwald, A., Weisenberger, T., Khalifa, A., … (2024). Short cell cycle duration is a phenotype of human epidermal stem cells. Stem Cell Research & Therapy, 15(1), 76.

2. Elsabagh, R. H., Farghali, H. A. M., Emam, I. A., Ragab, E., … (2021). Quantitative flow cytometry assessment of feline circulatory breast cancer stem cells. Advances in Animal and Veterinary Sciences, 9(12), 2201–2215.

3. Elsabagh, R. H., Farghali, H. A. M., Emam, I. A., Abdelrahman, H. H., Ragab, E., … (2025). Gold nano-rod (AuNR)-mediated plasmonic photothermal therapy in feline mammary carcinoma: Assessing metastatic and nonmetastatic outcomes. Veterinary Oncology, 2(1), 33.

4. Elsabagh, R. H., Farghali, H. A. M., Emam, I. A., Abdelrahman, H., Ragab, E., … (2022). Prevention of in situ recurrence and distant metastasis in feline mammary carcinoma treated with plasmonic photothermal therapy.

 

Huiling Chen | Oncology | Best Researcher Award

Published on by Health Scientists

Dr. Huiling Chen | Oncology | Best Researcher Award 

Physician | Lanzhou University | China

Dr. Huiling Chen is a distinguished physician and researcher at The Second Hospital and Clinical Medical School, Lanzhou University, recognized for her significant contributions to the field of hematologic malignancies, particularly acute myeloid leukemia (AML). Her research primarily focuses on advancing evidence-based therapeutic strategies through systematic reviews and meta-analyses that inform clinical decision-making and improve patient outcomes. As the lead investigator and corresponding author of a comprehensive meta-analysis published in the Annals of Hematology, Dr. Chen evaluated the efficacy and safety of venetoclax plus azacitidine regimens in relapsed or refractory AML, providing vital insights into their clinical utility and identifying combination chemotherapy as a promising approach for improving remission outcomes. Her expertise lies in clinical epidemiology, biostatistics, and the design and interpretation of complex data in oncology research. Through collaborations with multidisciplinary teams across national and international institutions, she has contributed to multicenter studies that bridge gaps between clinical research and real-world applications. Her scholarly work exemplifies a commitment to scientific rigor, innovation, and translational relevance, with her findings influencing the direction of future clinical trials and treatment paradigms for high-risk AML populations. Dr. Chen’s research efforts aim to optimize therapeutic interventions, enhance personalized treatment planning, and advance precision medicine in hematology. Beyond her academic accomplishments, she upholds a strong dedication to mentoring and fostering collaborative research environments that encourage cross-institutional partnerships and scientific dialogue. Her contributions embody the integration of analytical excellence, clinical insight, and humanitarian vision, underscoring her role as a leader shaping the future of hematologic cancer research and its impact on global health.

Profile: ORCID 

Featured Publications

1. Chen, H., Li, X., Gao, L., Zhang, D., & Han, T. (2022, August). Construction and identification of an immortalized rat intestinal smooth muscle cell line. Neurogastroenterology & Motility.

2. Chen, H., Ren, X., Xu, S., Zhang, D., & Han, T. (2022, July). Optimization of lipid nanoformulations for effective mRNA delivery. International Journal of Nanomedicine.

3. Chen, H., Han, T., Gao, L., & Zhang, D. (2022, January). The involvement of glial cell-derived neurotrophic factor in inflammatory bowel disease. Journal of Interferon & Cytokine Research.

4. Chen, H., Zeng, P., & Zhang, D. (2020, February). Haemophagocytic syndrome triggered by acute lymphoblastic leukaemia with t(9;22)(p24; q11.2). Journal of International Medical Research.

Niladry Sekhar Ghosh | Oncology | Best Researcher Award

Published on by Health Scientists

Prof. Niladry Sekhar Ghosh | Oncology | Best Researcher Award

Professor | Assam Down Town University, Guwahati | India

Prof. Niladry Sekhar Ghosh is a distinguished researcher and Professor at Assam Down Town University, Guwahati, serving also as Member Secretary of the Board of Studies, with extensive expertise in pharmaceutical sciences, medicinal chemistry, and biomedical research. He earned his B.Pharm. and M.Pharm. degrees from S.C.S College of Pharmacy, R.G.U.H.S Bangalore, graduating with first-class honors, and completed his Ph.D. at Shobhit University in 2020, focusing on the synthesis of bioactive fluoro-benzothiazole derivatives and the biosynthesis of metallic nanoparticles for biological and pharmacological screening. With over 18 years of teaching experience and significant contributions to research, his key areas of interest include drug discovery, medicinal chemistry, nanotechnology-based drug delivery systems, pharmacological evaluation of bioactive compounds, and cancer therapeutics. Prof. Ghosh has authored more than 50 publications in high-impact journals indexed in SCI, Scopus, and ESCI, including studies on cathepsin inhibitors, benzimidazole and indole derivatives as anticancer agents, and green synthesis of nanoparticles. He has been recognized with multiple honors, notably the Young Teacher Awards by SPER in 2016 and 2018, and has secured competitive research grants from SERB-DST, DBT, ICMR, and NCW for innovative projects in pharmaceutical biotechnology and nanomedicine. Additionally, he holds patents for metallic nanoparticle synthesis and biomedical devices. Beyond research, he serves as a resource person, reviewer, and editor for various scientific journals, contributing to the dissemination of knowledge in medicinal chemistry, pharmacology, and nanotechnology. His leadership roles in academic administration and research guidance underscore his commitment to advancing pharmaceutical education and translational research. He has 90 citations from 22 documents with an h-index of 7.

Profiles: Google Scholar | Scopus | ORCID

Featured Publications

1. Dubey, A., Ghosh, N. S., & Singh, R. (2022). Zebrafish as an emerging model: An important testing platform for biomedical science.

2. Dubey, A., Ghosh, N. S., Gupta, A., & Singh, S. (2023). A review on current epidemiology and molecular studies of lumpy skin disease virus—An emerging worldwide threat to domestic animals.

3. Dubey, A., Ghosh, N. S., Agnihotri, N., Kumar, A., Pandey, M., & Nishad, S. (2022). Herbs derived bioactive compounds and their potential for the treatment of neurological disorders.

4. Dubey, A., Ghosh, N. S., Rathor, V. P. S., Patel, S., Patel, B., & Purohit, D. (2022). SARS-CoV-2 infection leads to neurodegenerative or neuropsychiatric diseases.

5. Chandra, D., Yadav, I. K., Jaiswal, D., Ghosh, N., Singh, H. P., Mishra, A., … (Year not specified). Formulation and evaluation of satranidazole microspheres for colon-targeted drug delivery.